Treatment of infantile haemoangioma – Update 2016

Summary

Aim Complicated infantile hemangioma need early, safe and effective treatment. The aim of this study was to provide greater insight into systemic and topical propranolol treatment efficacy and side effects.

Methods We report our retrospective experiences of 207 paediatric patients treated with systemic propranolol and of 148 paediatric patients treated with propranolol gel topically photographed and analysed with a specific hemangioma score.

Results Propranolol treatment was successful in >99 % of the patients. The hemangioma score showed a significant decrease during systemic treatment (8.3 ± 3.3 at beginning and 1.5± 1.4 after 6 months) and during topical treatment (4.2 ± 1,6 at beginning and 2.2 ± 1.3 after three months). Systemic treatment did not show any differences when distributed according to different localizations or to the patient`s ages. During topical propranolol treatment relevant serum levels were not determined. Relevant side effects that may have made it necessary to discontinue the treatment were not observed. However, there was a statistically significant reduction in heart rate but not in mean arterial blood pressure during the first six in-hospital systemic drug applications.

Conclusion Systemic propranolol treatment is highly effective and nearly always safe. Topical treatment with propranolol gel (off-label) is suitable for specific hemangioma in addition to cryotherapy and systemic treatment with propranolol. These findings provide highly valuable information on this drug treatment for complicated infantile hemangioma in infants.

Keywords

Infantile hemangioma - propranolol - β-blocker - systemic and topical treatment

• References

• 1 Darrow D H, Green A K, Mancini A J, Nopper A J. Diagnosis and Management of infantile hemangioma. Pediatrics 2015; 136: e1060-1104.
• 2 Itinteang T, Withers A H J, Davis P F, Tan S T. Biology of infantile hemangioma. Front Surg 2014; 01: 1-9.
• 3 Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taieb A. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358: 2649-2651.
• 4 Handgretinger R. How an accidental discovery paved the way for the treatment of complicated infantile haemangiomas. Acta Paed 2014; 103: 896-897.
• 5 Wu S, Wang B, Chen L, Xiong S, Zhuang F, Huang X, Wang M, Huang Z. Clinical efficacy of propranolol in the treatment of hemangioma and changes in serum VEGF, bFGF and MMP-9. Exp Ther Med 2015; 10: 1079-1083.
• 6 Itinteang T, Withers A H J, Leadbitter P, Day D J, Tan S T. Reply: Pharmacologic therapies for infantile hemangioma: Is there a rational basis?. Plastic Reconstr Surg 2012; 129: 725e-727e.
• 7 Ji Y, Chen S, Xu C, Li L, Xiang B. The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action. Br J Dermatol 2015; 172: 24-32.
• 8 Schneider M, Cremer H J, Ruef P. A retrospective analysis of systemic propranolol for the treatment of complicated infantile haemangiomas. Acta Paed 2014; 103: 977-983.
• 9 Schneider M, Reimer A, Cremer H J, Ruef P. Topical treatment with propranolol gel as a supplement to the existing treatment of hemangiomas. World J Pediatr 2014; 10: 313-317.
• 10 Glantz S A. Alternatives to analysis of variance and the t-test based on ranks. In: Glantz S A. Primer of biostatistics. New York: McGraw-Hill; 2005: 363-412.
• 11 Tan C E, Itinteang T, Leadbitter P, Marsh R, Tan S T. Low-dose propranolol regimen for infantile haemangioma. J Paediatr Child Health 2015; 51: 419-424.
• 12 Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G, Phillips RJ, Caceres H, Lopez J CGutierrez, Ballona R, Friedlander S F, Powell J, Perek D, Metz B, Barbarot S, Maruani A, Szalai Z Z, Krol A, Boccara O, Foelster-Holst R, Febrer M IBosch, Su J, Buckova H, Torrelo A, Cambazard F, Grantzow R, Wargon O, Wyrzykowski D, Roessler J, Bernabeu-Wittel J, Valencia A M, Przewratil P, Glick S, Pope E, Birchall N, Benjamin L, Mancini A J, Vabres P, Souteyrand P, Frieden I J, Berul C I, Mehta C R, Prey S, Boralevi F, Morgan C C, Heritier S, Delarue A, Voisard J J. A rangomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med 2015; 327: 735-746.
• 13 Wedgeworth E, Glover M, Irvine A D, Neri I, Baselga E, Clayton T H, Beattie P E, Bjerre J V, Burrows N P, Foelster-Holst R, Hedelund L, Hernandez-Martin A, Audrain H, Bhate K, Brown S J, Baryschpolec S, Darne S, Durack A, Dvorakova V, Gach J. Propranolol in the treatment of infantile haemangiomas: lessons from the European Propranolol In the Treatment of Complicated Haemangiomas ( PITCH) Taskforce survey. Br J Dermatol 2016; 174: 594-601.
• 14 Tozzi A. Oral Propranolol for Infantile Hemangioma. N Engl J Med 2015; 373: 284.
• 15 Langley A, Pope E. Propranolol and central nervous system function: potential implications for pediatric patients with infantile haemangiomas. Br J Dermatol 2015; 172: 13-23.
• 16 Moyakine A V, Kerstjens J M, Spillekom-van Koulil S, van der Vleuten C J M. Propranolol treatment of infantile hemangioma (ICH) is not associated with developmental risk or growth impairment a tage 4 years. J Am Acad Dermatol 2016; 75: 59-63.
• 17 Frommelt P, Juern A, Siegel D, Holland K, Seefeldt M, Yu J, Uhing M, Wade K, Drolet B. Adverse events in young and preterm infants receiving topical timolol for infantile hemangioma. Pediatr Dermatol 2016; 1-10 doi: 10.1111/pde.12869.